NR1I3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL241281	1.00	18/20
SCHEMBL241282	1.00	18/20
SCHEMBL257597	0.42	5/20
Moricizine (SCHEMBL16794)	0.73	4/20
Moricizine (SCHEMBL41358)	0.72	4/20
Moricizine (SCHEMBL41359)	0.72	4/20
SCHEMBL365051	0.43	4/20
Lumiracoxib (SCHEMBL4479)	1.00	2/20
Glimepiride (SCHEMBL16084)	1.00	2/20
Glimepiride (SCHEMBL16086)	1.00	2/20
Androstenol (SCHEMBL324888)	1.00	2/20
SCHEMBL397787	0.72	2/20
SCHEMBL16085	0.71	2/20
Eltenac (SCHEMBL145080)	0.67	2/20
SCHEMBL156889	0.65	2/20
SCHEMBL156890	0.65	2/20
SCHEMBL317214	0.51	2/20
SCHEMBL397432	0.49	2/20
SCHEMBL443120	0.49	2/20
SCHEMBL60445	0.47	2/20

Clinical trials — most relevant to NR1I3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate	PHASE4	NOT_YET_RECRUITING
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis	PHASE3	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer	PHASE1/PHASE2	RECRUITING
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer	PHASE2	UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	PHASE2	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Metabolic Investigation, Physical Performance, Physical Training At Different Times of the Day in Obese Women	nan	ACTIVE_NOT_RECRUITING
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
LXR and Oocyte Meiosis Resumption	nan	UNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling	nan	COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)	nan	RECRUITING
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients	nan	COMPLETED
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR1I3 binder may also engage these)

Protein	Name	Similarity
A2T7D9	—	1.000	A2T7D9 →
P62044	—	1.000	P62044 →
O35627	—	1.000	O35627 →
Q8MIM3	—	1.000	Q8MIM3 →
P62045	—	0.997	P62045 →
Q5E9B6	—	0.994	Q5E9B6 →
Q9QUS1	—	0.994	Q9QUS1 →
NR1I2	Nuclear receptor subfamily 1 group I member 2	0.990	landscape →
P18119	—	0.990	P18119 →
NR1H2	Oxysterols receptor LXR-beta	0.989	landscape →
Q9W785	—	0.988	Q9W785 →
Q62755	—	0.988	Q62755 →
O57606	—	0.988	O57606 →
Q9W6N4	—	0.988	Q9W6N4 →
NR1H3	Oxysterols receptor LXR-alpha	0.987	landscape →
F1QLY4	—	0.987	F1QLY4 →
VDR	Vitamin D3 receptor	0.987	landscape →
Q28037	—	0.987	Q28037 →
Q62685	—	0.987	Q62685 →
Q90382	—	0.987	Q90382 →
Q91241	—	0.987	Q91241 →
P68305	—	0.987	P68305 →
Q91279	—	0.986	Q91279 →
P04625	—	0.985	P04625 →
Q91242	—	0.983	Q91242 →
A3RGC1	—	0.983	A3RGC1 →
Q9TTF0	—	0.983	Q9TTF0 →
Q28570	—	0.983	Q28570 →
Q02777	—	0.983	Q02777 →
P18115	—	0.982	P18115 →